4//SEC Filing
Torley Helen 4
Accession 0001159036-25-000063
CIK 0001159036other
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 7:31 PM ET
Size
15.8 KB
Accession
0001159036-25-000063
Insider Transaction Report
Form 4
Torley Helen
DirectorPresident and CEO
Transactions
- Gift
Common Stock
2025-11-26−25,000→ 708,719 total - Exercise/Conversion
Common Stock
2025-12-01$8.11/sh+16,569$134,375→ 725,288 total - Sale
Common Stock
2025-12-01$68.51/sh−10,406$712,936→ 714,882 total - Sale
Common Stock
2025-12-01$69.44/sh−5,402$375,120→ 709,480 total - Sale
Common Stock
2025-12-01$70.36/sh−500$35,181→ 708,980 total - Sale
Common Stock
2025-12-01$71.60/sh−261$18,688→ 708,719 total - Exercise/Conversion
Option to Purchase Common Stock
2025-12-01$8.11/sh−16,569$134,375→ 0 totalExercise: $8.11Exp: 2026-02-03→ Common Stock (16,569 underlying)
Footnotes (6)
- [F1]Represents a bona fide gift to charity.
- [F2]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.160 to $70.100. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.160 to $70.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.
Documents
Issuer
HALOZYME THERAPEUTICS, INC.
CIK 0001159036
Entity typeother
Related Parties
1- filerCIK 0001528185
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 7:31 PM ET
- Size
- 15.8 KB